)
Sadik Kassim
Chief Technology Officer,
Danaher Life Sciences
Sadik Kassim, Ph.D., is a biotechnology executive and scientist specializing in cell and gene therapy, bioprocessing, and translational research. He serves as CSO/CTO of Genomic Medicines for Danaher’s Life Sciences companies. Previously, he was CTO at Vor Bio, where he built technical operations and advanced CRISPR-edited and CAR-T programs. He also held leadership roles at Kite Pharma, Mustang Bio, and Novartis, driving development and manufacturing of cell therapies. Dr. Kassim has contributed to three commercial CAR-T therapies and recent innovations in gene editing. He holds a Ph.D. from LSU and completed postdoctoral training at NCI, UPenn, and Johnson & Johnson.